Therapy of relapsing minimal-change disease in adults: a new approach?

Multiple-relapsing minimal-change disease (MCD) often requires exposure to potentially toxic agents in an attempt to achieve a lasting remission of nephrotic syndrome. Munyentwali and co-workers describe an experience using rituximab in adults with multiple-relapsing MCD that supports both efficacy and safety of this agent. However, the optimal dosing regimen and mechanism of action remain unclear. Thus, randomized controlled trials are warranted in both adults and children to better define the role of rituximab in multiple-relapsing MCD.
AuthorsRichard J Glassock
JournalKidney international (Kidney Int) Vol. 83 Issue 3 Pg. 343-5 (Mar 2013) ISSN: 1523-1755 [Electronic] United States
PMID23446250 (Publication Type: Comment, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Rituximab
  • Prednisone
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antigens, CD20 (immunology)
  • Female
  • Humans
  • Male
  • Nephrosis, Lipoid (drug therapy)
  • Prednisone (therapeutic use)
  • Rituximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: